LORELEI trial: Treatment with alpha specific PI3K inhibitor reduces breast tumor size

[News]

Adding taselisib to letrozole before surgery significantly improved outcomes for patients with early breast cancer that was both estrogen receptor positive and HER2-negative (ER+/HER2-) according to results of the LORELEI trial, presented at the ESMO 2017 Congress in Madrid.

More... (https://www.news-medical.net/news/20170908/LORELEI-trial-Treatment-with-alpha-specific-PI3K-inhibitor-reduces-breast-tumor-size.aspx)